Literature DB >> 24629518

Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.

Woo Jin Lee1, Joon Min Jung1, Chong Hyun Won1, Sung Eun Chang1, Jee Ho Choi1, Kee Chan Moon1, Chan-Sik Park2, Jooryung Huh2, Mi Woo Lee3.   

Abstract

BACKGROUND: Differences in survival outcomes and prognostic factors of cutaneous extranodal natural killer/T-cell lymphoma (ENKTL) depending on primary tumor site are currently unknown.
OBJECTIVE: We sought to analyze the clinicopathological features and survival outcomes of cutaneous ENKTL according to primary tumor site.
METHODS: In all, 45 patients with cutaneous ENKTL were classified with: (1) primary cutaneous ENKTL, or (2) nasal ENKTL with cutaneous involvement. Clinicopathologic features, survival outcomes, and prognostic factors were analyzed using patient's medical records. Survival outcomes were analyzed using the Kaplan-Meier method and compared using the log rank test. The Student t test, Fisher exact test, and linear by linear association test were used to analyze clinicopathologic differences between groups.
RESULTS: Clinical manifestations of cutaneous ENKTL included solitary or multiple subcutaneous nodules and cellulitis or abscess-like lesions. Primary cutaneous ENKTL demonstrated a less aggressive clinical course and better survival outcomes. The extent of cutaneous lesions demonstrated a significant effect on the prognosis of primary cutaneous ENKTL, but not on nasal ENKTL with cutaneous involvement. The presence of nasal lesions in primary cutaneous ENKTL was associated with poor prognosis. LIMITATIONS: This study used a retrospective design and included a small sample size.
CONCLUSION: Although the clinicopathological features were similar regardless of subgroup, survival outcomes and prognostic factors differed depending on the primary tumor site of cutaneous ENKTL.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  cutaneous lesion; extranodal natural killer/T-cell lymphoma; prognostic factor; skin; survival outcome; tumor site

Mesh:

Year:  2014        PMID: 24629518     DOI: 10.1016/j.jaad.2013.12.023

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Subcutaneous nodules as the presenting symptom of diffuse large B cell lymphoma.

Authors:  Bik Ling Man; Kit Kwan Ma; Yat Pang Fu
Journal:  BMJ Case Rep       Date:  2014-11-05

2.  Correlation between the prevalence of T-cell lymphomas and alcohol consumption.

Authors:  Minodora Desmirean; Cedric Richlitzki; Sergiu Pasca; Patric Teodorescu; Bobe Petrushev; Sebastian Rauch; Jacob Steinheber; Sabina Iluta; Jiaxin Liu; Delia Dima; Ravnit Grewal; Weina Ma; Liren Qian; Ciprian Tomuleasa
Journal:  Med Pharm Rep       Date:  2021-07-29

3.  Annular Erythematous Patches as the Presenting Sign of Extranodal Natural Killer/T-Cell Lymphoma.

Authors:  Can Baykal; Algün Polat Ekinci; Şule Öztürk Sarı; Zeynep Topkarcı; Özgür Demir; Nesimi Büyükbabani
Journal:  Turk J Haematol       Date:  2016-07-15       Impact factor: 1.831

4.  Extranodal natural killer/T-cell lymphoma, nasal type, involving the skin, misdiagnosed as nasosinusitis and a fungal infection: A case report and literature review.

Authors:  Yan Zheng; Jinjing Jia; Wensheng Li; Juan Wang; Qiong Tian; Zhengxiao Li; Jing Yang; Xinyu Dong; Ping Pan; Shengxiang Xiao
Journal:  Oncol Lett       Date:  2014-09-08       Impact factor: 2.967

5.  Multifocal primary cutaneous extranodal NK/T lymphoma nasal type.

Authors:  Pedro de Vasconcelos; Cristina Ferreira; Luís Soares-Almeida; Paulo Filipe
Journal:  An Bras Dermatol       Date:  2016-04       Impact factor: 1.896

6.  Clinicopathological characteristics and treatment outcomes of cutaneous extranodal natural killer/T-cell lymphoma: a retrospective study in China.

Authors:  Xi Chen; Xiaoling Liu; Weiping Liu; Lin Wang; Liqun Zou
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.